Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00359164
Status:
COMPLETED
Last Update Posted:
2008-08-14
First Post:
2006-07-28
Brief Title:
Phase II Pilot Study of Visudyne Photodynamic Therapy PDT Low and Very Low Fluence Combined With Bevacizumab
Sponsor:
University of British Columbia
Organization:
University of British Columbia
Study Overview
Official Title:
A Randomized Controlled Double-Masked Phase II Pilot Study of Visudyne Photodynamic Therapy PDT Low and Very Low Fluence Combined With Bevacizumab Avastin in Patients With Subfoveal Choroidal Neovascularization CNV Secondary to Age Related Macular Degeneration AMD
Status:
COMPLETED
Status Verified Date:
2008-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To determine if Visudyne photodynamic therapy low or very low fluence rate combined with intravitreal injections of bevacizumab Avastin compared with bevacizumab alone will with similar safety and efficacy delay time to retreatment with bevacizumab after the initial treatment in subjects with new wet AMD Hypothesis PDT in combination with Avastin at either the low or very low fluence rate will delay time to retreatment and reduce the average number of treatments required compared to Avastin alone but will have a similar safety and efficacy profile
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| V06-0157 | None | None | None |